Alluvi Tirzepatide 40mg (Mounjaro)
£135.00
Alluvi Tirzepatide 40mg is a research-grade formulation supplied for controlled laboratory and scientific research applications. Tirzepatide is a dual GIP and GLP-1 receptor agonist and is the active substance in Mounjaro, making it a significant compound in modern metabolic research.
Research into Tirzepatide focuses on the interaction between GIP and GLP-1 signalling pathways and their relevance to glucose metabolism, metabolic regulation, energy balance and body-weight research.
The 40mg Alluvi formulation provides a defined research compound for qualified researchers investigating dual incretin receptor activity, metabolic signalling and weight-management research models.
40mg Tirzepatide formulation
Dual GIP and GLP-1 receptor research profile
Active substance in Mounjaro
Suitable for metabolic and weight-management research
For laboratory research use only. Not for human or veterinary use.
Advanced Dual GIP & GLP-1 Research Peptide
Alluvi Tirzepatide 40mg is a research-grade peptide formulation supplied exclusively for controlled laboratory, analytical and scientific research applications.
Tirzepatide is a synthetic peptide that acts on two important metabolic receptor pathways:
- GIP — Glucose-Dependent Insulinotropic Polypeptide
- GLP-1 — Glucagon-Like Peptide-1
Tirzepatide is also the active substance in Mounjaro, an authorised medicinal product containing tirzepatide. The Mounjaro reference provides important pharmaceutical context for the compound, while Alluvi Tirzepatide 40mg is supplied separately as a research product and is not Mounjaro or an authorised medicinal product.
Tirzepatide’s Dual-Pathway Research Profile
GIP Receptor Research
GIP signalling is investigated in relation to:
- Incretin biology
- Glucose metabolism
- Insulin-related signalling
- Energy regulation
- Metabolic research
GIP receptor activity forms one half of Tirzepatide’s dual-receptor research profile.
GLP-1 Receptor Research
GLP-1 receptor signalling is studied in relation to:
- Glucose regulation
- Appetite-related signalling
- Metabolic pathways
- Energy balance
- Gastrointestinal research
The combined GIP and GLP-1 activity makes Tirzepatide a significant subject of research into multi-pathway metabolic signalling.
Tirzepatide and Metabolic Research
Research into Tirzepatide has focused on how combined GIP and GLP-1 receptor activity may influence metabolic processes.
Research areas include:
- Glucose metabolism
- Metabolic signalling
- Energy balance
- Appetite-related pathways
- Body-weight regulation
- Weight-management research models
- Incretin receptor biology
- Comparative peptide research
The dual-receptor profile allows researchers to investigate the interaction between two important metabolic signalling pathways within controlled research environments.
Tirzepatide and Mounjaro: Important Context
Tirzepatide is the active substance in Mounjaro. This pharmaceutical association has contributed to the compound’s significant scientific and clinical research interest.
However, it is important to distinguish between the active substance and the finished medicinal product:
Alluvi Tirzepatide 40mg is a research product and is not Mounjaro.
The product is supplied for laboratory research and scientific investigation only and must not be presented as an equivalent, substitute or alternative to prescribed Mounjaro.
Research Applications
Qualified researchers may investigate Alluvi Tirzepatide 40mg in areas including:
- Metabolic research
- GLP-1 receptor research
- GIP receptor research
- Dual incretin signalling
- Glucose metabolism
- Energy balance
- Body-weight regulation
- Weight-management research models
- Appetite-related signalling
- Comparative metabolic peptide research
- Receptor interaction studies
- Peptide development research
These represent areas of scientific investigation and are not approved medical or therapeutic applications of this research product.
Why Researchers Study Tirzepatide
Tirzepatide is of particular research interest because it combines activity across two major metabolic receptor pathways.
Studying GIP and GLP-1 activity together allows researchers to investigate:
- How dual-receptor signalling affects metabolic pathways
- The interaction between incretin-related mechanisms
- Glucose-regulation pathways
- Energy-balance signalling
- Body-weight regulation mechanisms
- Differences between single- and dual-receptor peptide compounds
Its established pharmaceutical context through Mounjaro also makes Tirzepatide an important compound for comparative research involving metabolic peptide mechanisms.
Product Features
- 40mg Tirzepatide formulation
- Dual GIP and GLP-1 receptor activity
- Active substance in Mounjaro
- Suitable for metabolic research
- Suitable for glucose-metabolism research
- Suitable for body-weight regulation research models
- Suitable for weight-management research
- Research-grade peptide formulation
- For laboratory research use only
Product Information
Product Name: Alluvi Tirzepatide 40mg
Compound: Tirzepatide
Strength: 40mg
Research Profile: Dual GIP and GLP-1 receptor agonist
Product Type: Research peptide formulation
Brand: Alluvi
Application: Laboratory research and scientific investigation only
Important Research Use Notice
Alluvi Tirzepatide 40mg is supplied strictly for laboratory research and scientific investigation.
This product is:
- Not Mounjaro
- Not an authorised medicinal product
- Not intended for human consumption
- Not intended for veterinary use
- Not intended as a weight-loss treatment
- Not intended to diagnose, treat, cure or prevent any disease
All research compounds should be handled by appropriately qualified personnel in accordance with applicable laboratory procedures and regulations.
Related products
Reviews
There are no reviews yet.